Syros' CDK12 Inhibitor Shows Anti Tumor Activity In Preclinical Studies

Syros Pharmaceuticals Inc SYRS announced new preclinical data from its CDK12 inhibitor program, demonstrating robust anti-tumor activity in models of breast, lung, and ovarian cancer, including in a PARP inhibitor-resistant model. 

• The data support the advancement of a development candidate from Syros' CDK12 inhibitor program towards clinical development. 
• As a single agent in cancer cell models, the CDK12 inhibitor induced DNA damage, cell cycle dysregulation, and genomic instability leading to growth inhibition and apoptosis. 
• Additionally, as a single agent in in vivo cancer models, the Company's CDK12 inhibitor demonstrated tumor regressions in small cell lung cancer and breast cancer models at well-tolerated doses.
• Related: Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings.
• In combination in vitro, the CDK12 inhibitor exhibited synergistic or additive antiproliferative effects with lurbinectedin and olaparib, with increases in DNA damage and impaired DNA damage repair. 
• Lurbinectedin is marketed by Jazz Pharmaceutical Inc JAZZ as Zepzelca and AstraZeneca Plc AZN - Merck & Co Inc's MRK market olaparib under Lynparza name.
• Price Action: SYRS shares are down 7.83% at $1.06 during the premarket session on the last check Monday.